Back to results
US 2022/0064295 A1Published application
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AssigneeITabMed (HK) Limited
InventorsZhihua HUANG, Wuzhong SHEN, Yiqun RAO, Yuin CUI, Xaoqiang YAN
Life of this patent
Estimating the term…
Abstract
Provided are multispecific antigen binding proteins (MSAPs) that specifically bind to CD3 and CD19. Further provided are uses of the MSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSAPs.
Claims25
A multispecific antigen binding protein comprising:
- I. an anti-CD3 Fab fragment that specifically binds to CD3, wherein the anti-CD3 Fab fragment comprises:
- (a) an immunoglobulin (Ig) heavy chain variable region (VH) and an Ig heavy chain constant region (CH1);
- and
- (b) an Ig light chain variable region (VL) and an Ig light chain constant region (CL);
- II. an anti-CD19 antigen binding fragment that specifically binds to CD19;
- and
- III. optionally, a linker connecting the anti-CD3 Fab fragment and the anti-CD19 antigen binding fragment.
4 more elements
5-6. (canceled)
9-12. (canceled)
19-20. (canceled)
28-29. (canceled)
(canceled)
Dependencies are inferred from the claim text.